National Institutes of Health (NIH) Launches First Large Trial of a Long-Acting Injectable Drug for HIV Prevention

Study to Test Efficacy, Safety of Injectable Cabotegravir Compared to Daily Oral PrEP
NIH, December 20, 2016

Read online at:
https://www.niaid.nih.gov/news-events/nih-launches-first-large-trial-long-acting-
injectable-drug-hiv-prevention

The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet. If injectable cabotegravir is found to be effective for HIV pre-exposure prophylaxis, also known as PrEP, it may be easier for some people to adhere to than daily oral Truvada, the only licensed PrEP regimen.

(Visited 12 times, 1 visits today)
This entry was posted in Essential Medicines, General, HIV - AIDS - STI. Bookmark the permalink.